Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies

Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies: a Retrospective Cohort Based on SEER Database From 2000-2021

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06978595

Enrollment

8171

Registered

2025-05-18

Start date

2000-01-01

Completion date

2021-12-30

Last updated

2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Colorectal Carcinoma, Signet Ring Adenocarcinoma of the Colon

Keywords

signet ring carcinoma, SEER, Cancer

Brief summary

This original research investigates the critical issue of gastrointestinal (GI) second primary malignancies (SPMs) in patients with signet ring cell carcinoma (SRCC), a rare and aggressive subtype of colorectal cancer. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, the investigators assessed the risk of GI SPMs, particularly within 2-11 months post-SRCC diagnosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with primary colorectal SRCC between 2000 and 2021 * Latency exclusion period of two months

Exclusion criteria

* patients with unknown age data

Design outcomes

Primary

Measure	Time frame	Description
The standardized incidence ratio of developing gastrointestinal second primary malignancies following primary colorectal signet ring cell carcinoma	from Jan, 2000 till Dec, 2021	The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) for second primary gastrointestinal malignancies. Patients diagnosed with primary colorectal SRCC between 2000 and 2021 were included. The event was defined as the appearance of an SPM in a different site from the original cancer at a new GI organ (esophagus, stomach, small intestine, cecum, appendix, rectum, anus and anal canal, liver, gallbladder, intrahepatic bile duct, pancreas, retro-peritoneum, and colon).

Secondary

Measure	Time frame	Description
The excess risk of developing gastrointestinal second primary malignancies following primary colorectal signet ring cell carcinoma	from Jan, 2000 till Dec, 2021	The excess risk per 10,000 was calculated using SEER\*stat software.

Countries

Egypt

Outcome results